Press Releases.

Regulus Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

LA JOLLA, Calif., Jan. 6, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the grant of an inducement stock option to Joseph P. "Jay" Hagan on January 4, 2016 in connection with his employment with Regulus.  Regulus previously announced the appointment of Mr. Hagan as Regulus' Chief Operating Officer, effective January 4, 2016.  Mr. Hagan's inducement stock option is exercisable for up to 376,246 shares of Regulus' common stock at an exercise price per share equal to $8.57, the fair market value on the grant date.  The stock option vests over four years, with 25% of the underlying shares vesting after one year and the balance of the underlying shares vesting on a monthly basis thereafter, subject in each case to Mr. Hagan's continued service relationship with Regulus. 

Regulus Therapeutics Inc. Logo

The stock option has a ten year term and is subject to the terms and conditions of Regulus' Inducement Plan and stock option grant notice and agreement thereunder. 

The stock option grant was granted as an inducement material to Mr. Hagan entering into employment with Regulus Therapeutics Inc. in accordance with NASDAQ listing Rule 5635(c)(4).

About Regulus

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a maturing microMarkersSM biomarkers platform and a rich intellectual property estate to retain its leadership in the microRNA field.  Under its 'Clinical Map Initiative', Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection, and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy.  In addition, RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of NASH in patients with type 2 diabetes/pre-diabetes, has entered Phase I clinical development through its strategic alliance with AstraZeneca.  Regulus is also advancing several programs toward clinical development in orphan disease indications, oncology and fibrosis.  Regulus' commitment to innovation has resulted in multiple peer-reviewed publications in notable scientific journals and has resulted in the formation of strategic alliances with AstraZeneca and Sanofi and a research collaboration with Biogen focused on microRNA biomarkers.  Regulus maintains its corporate headquarters in La Jolla, CA.  For more information, please visit

Forward-Looking Statements  

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Logo -


To view the original version on PR Newswire, visit:

SOURCE Regulus Therapeutics Inc.

For further information: Investor Relations Contact, Amy Conrad, Regulus Therapeutics Inc., 858-202-6321,; Media Contact, Liz Bryan, Spectrum Science, 202-955-6222 x2526,